ES2630705T3 - Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas - Google Patents

Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas Download PDF

Info

Publication number: ES2630705T3
Authority: ES; Spain
Prior art keywords: substituted; alkyl; hydrogen; heteroatoms selected; rnrbc
Prior art date: 2012-01-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES13700829.8T

Other languages

English (en)

Spanish (es)

Inventor

Dharmpal S. Dodd

Christopher P. Mussari

Rajeev S. Bhide

Satheesh Kesavan NAIR

Venkatram Reddy PAIDI

Sreekantha Ratna KUMAR

Abhisek Banerjee

Ramesh Sistla

William J. Pitts

John Hynes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-13

Filing date

2013-01-11

Publication date

2017-08-23

2013-01-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2017-08-23 Application granted granted Critical

2017-08-23 Publication of ES2630705T3 publication Critical patent/ES2630705T3/es

Status Active legal-status Critical Current

2033-01-11 Anticipated expiration legal-status Critical

Links

125000001425 triazolyl group Chemical group 0.000 title claims abstract description 8
125000004076 pyridyl group Chemical group 0.000 title claims description 10
229940043355 kinase inhibitor Drugs 0.000 title description 3
239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
229910052760 oxygen Inorganic materials 0.000 claims abstract description 69
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 61
239000001257 hydrogen Substances 0.000 claims abstract description 61
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 59
229910052717 sulfur Inorganic materials 0.000 claims abstract description 54
125000005842 heteroatom Chemical group 0.000 claims abstract description 53
150000001875 compounds Chemical class 0.000 claims abstract description 41
150000002431 hydrogen Chemical group 0.000 claims abstract description 39
-1 cyclic acetal Chemical class 0.000 claims abstract description 37
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 36
229910052801 chlorine Inorganic materials 0.000 claims abstract description 29
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 28
229910052794 bromium Inorganic materials 0.000 claims abstract description 27
229910052731 fluorine Inorganic materials 0.000 claims abstract description 27
101150105130 RORB gene Proteins 0.000 claims abstract description 23
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 22
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract description 21
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 18
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 18
150000003839 salts Chemical class 0.000 claims abstract description 18
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 14
125000000217 alkyl group Chemical group 0.000 claims abstract description 12
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 12
125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract description 11
125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract description 11
125000005843 halogen group Chemical group 0.000 claims abstract description 9
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims abstract description 8
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 8
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 8
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 7
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims abstract description 7
108010081348 HRT1 protein Hairy Proteins 0.000 claims abstract description 7
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims abstract description 7
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims abstract description 5
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
150000002367 halogens Chemical class 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 8
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 8
125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
125000005872 benzooxazolyl group Chemical group 0.000 claims description 4
125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 4
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 claims description 4
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 4
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 4
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 15
239000000460 chlorine Substances 0.000 description 13
101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 9
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 9
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 9
102000002689 Toll-like receptor Human genes 0.000 description 9
108020000411 Toll-like receptor Proteins 0.000 description 9
230000011664 signaling Effects 0.000 description 9
101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 6
102000000589 Interleukin-1 Human genes 0.000 description 5
108010002352 Interleukin-1 Proteins 0.000 description 5
102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
201000005569 Gout Diseases 0.000 description 4
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 4
229940127590 IRAK4 inhibitor Drugs 0.000 description 4
102000019223 Interleukin-1 receptor Human genes 0.000 description 4
108050006617 Interleukin-1 receptor Proteins 0.000 description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
102100024324 Toll-like receptor 3 Human genes 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
230000000694 effects Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
206010018634 Gouty Arthritis Diseases 0.000 description 2
101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
102000039996 IL-1 family Human genes 0.000 description 2
108091069196 IL-1 family Proteins 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 2
102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
201000004982 autoimmune uveitis Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000012453 solvate Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000011594 Autoinflammatory disease Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000003927 aminopyridines Chemical class 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
230000036039 immunity Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
239000000203 mixture Chemical group 0.000 description 1
239000003607 modifier Substances 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
108091008743 testicular receptors 4 Proteins 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

ES13700829.8T 2012-01-13 2013-01-11 Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas Active ES2630705T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261586139P	2012-01-13	2012-01-13
US201261586139P		2012-01-13
PCT/US2013/021096 WO2013106614A1 (en)	2012-01-13	2013-01-11	Triazolyl-substituted pyridyl compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
ES2630705T3 true ES2630705T3 (es)	2017-08-23

Family

ID=47595098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES13700829.8T Active ES2630705T3 (es)	2012-01-13	2013-01-11	Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas

Country Status (6)

Country	Link
US (1)	US8987311B2 (2)
EP (1)	EP2802577B1 (2)
JP (1)	JP6096807B2 (2)
CN (1)	CN104169275B (2)
ES (1)	ES2630705T3 (2)
WO (1)	WO2013106614A1 (2)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2802576B1 (en)	2012-01-13	2018-06-27	Bristol-Myers Squibb Company	Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
ES2575604T3 (es) *	2012-01-13	2016-06-29	Bristol-Myers Squibb Company	Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
WO2014058685A1 (en)	2012-10-08	2014-04-17	Merck Sharp & Dohme Corp.	Inhibitors of irak4 activity
JP6215338B2 (ja)	2012-11-08	2017-10-18	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
BR112015009850A2 (pt)	2012-11-08	2017-07-11	Bristol Myers Squibb Co	compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
UY35935A (es)	2014-01-03	2015-06-30	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
HUE050317T2 (hu)	2015-05-20	2020-11-30	Amgen Inc	APJ receptor triazol agonistái
EP3313840B1 (en)	2015-06-24	2019-07-24	Bristol-Myers Squibb Company	Heteroaryl substituted aminopyridine compounds
US10618903B2 (en)	2015-06-24	2020-04-14	Bristol-Myers Squibb Company	Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) *	2015-06-24	2021-05-05	Bristol Myers Squibb Co	Compuestos de aminopiridina sustituidos con heteroarilo
US9988369B2 (en)	2016-05-03	2018-06-05	Amgen Inc.	Heterocyclic triazole compounds as agonists of the APJ receptor
CN106222183B (zh) *	2016-07-25	2019-11-08	南通大学	靶向人irak1基因的小干扰rna及其应用
US10323036B2 (en) *	2016-10-14	2019-06-18	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
US10736883B2 (en)	2016-11-16	2020-08-11	Amgen Inc.	Triazole furan compounds as agonists of the APJ receptor
EP3541803B1 (en)	2016-11-16	2020-12-23	Amgen Inc.	Triazole pyridyl compounds as agonists of the apj receptor
US11046680B1 (en)	2016-11-16	2021-06-29	Amgen Inc.	Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093576A1 (en)	2016-11-16	2018-05-24	Amgen Inc.	Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018093579A1 (en)	2016-11-16	2018-05-24	Amgen Inc.	Triazole phenyl compounds as agonists of the apj receptor
WO2018093577A1 (en)	2016-11-16	2018-05-24	Amgen Inc.	Cycloalkyl substituted triazole compounds as agonists of the apj receptor
TW202340194A (zh)	2017-02-16	2023-10-16	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
PT3621960T (pt)	2017-05-11	2021-09-16	Bristol Myers Squibb Co	Tienopiridinas e benzotiofenos úteis como inibidores de irak4
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
WO2019060742A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc	AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
MA50509A (fr)	2017-11-03	2021-06-02	Amgen Inc	Agonistes de triazole fusionnés du récepteur apj
EP3710443A1 (en)	2017-11-17	2020-09-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
WO2019126731A1 (en)	2017-12-22	2019-06-27	Petra Pharma Corporation	Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
WO2019140380A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
CN110317190A (zh) *	2018-03-28	2019-10-11	首都医科大学	一种三唑-羧酸酯类衍生物在医药领域的应用
US11807624B2 (en)	2018-05-01	2023-11-07	Amgen Inc.	Substituted pyrimidinones as agonists of the APJ receptor
WO2020010227A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
TWI842978B (zh) *	2018-07-13	2024-05-21	美商基利科學股份有限公司	衍生物
CA3119773A1 (en)	2018-11-30	2020-06-04	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
TW202112767A (zh)	2019-06-17	2021-04-01	美商佩特拉製藥公司	作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
PH12022500002A1 (en)	2019-06-28	2023-04-03	Kymera Therapeutics Inc	Irak degraders and uses thereof
WO2021011868A1 (en)	2019-07-17	2021-01-21	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
EP3999508B1 (en)	2019-07-18	2023-08-30	Bristol-Myers Squibb Company	Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021011727A1 (en)	2019-07-18	2021-01-21	Bristol-Myers Squibb Company	PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
US12304916B2 (en)	2019-07-23	2025-05-20	Bristol-Myers Squibb Company	Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
WO2021026181A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en)	2019-08-13	2026-03-24	Bristol Myers Squibb Co	Bicyclic heteroaryl compounds useful as irak4 inhibitors
WO2021119159A1 (en)	2019-12-10	2021-06-17	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
KR20220145325A (ko)	2019-12-17	2022-10-28	카이메라 쎄라퓨틱스 인코포레이티드	Irak 분해제 및 이의 용도
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
WO2021158495A1 (en)	2020-02-03	2021-08-12	Bristol-Myers Squibb Company	Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
US12421230B2 (en)	2020-02-03	2025-09-23	Bristol-Myers Squibb Company	Tricyclic heteroaryl compounds useful as IRAK4 inhibitors
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
MX2023003698A (es) *	2020-09-30	2023-06-15	Asahi Kasei Pharma Corp	Compuesto biciclico que contiene nitrogeno y pirimidina.
CN116867758A (zh)	2020-12-30	2023-10-10	凯麦拉医疗公司	Irak降解剂和其用途
US12171768B2 (en)	2021-02-15	2024-12-24	Kymera Therapeutics, Inc.	IRAK4 degraders and uses thereof
KR20240020735A (ko)	2021-05-07	2024-02-15	카이메라 쎄라퓨틱스 인코포레이티드	Cdk2 분해제 및 그 용도
CA3236265A1 (en)	2021-10-29	2023-05-04	William Leong	Irak4 degraders and synthesis thereof
CA3243560A1 (en)	2022-01-31	2023-08-03	Kymera Therapeutics, Inc.	Iraqi Degradation Agents and Their Uses
WO2026005537A1 (ko) *	2024-06-28	2026-01-02	주식회사 대웅제약	신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2450769A1 (en)	2001-06-15	2002-12-27	Vertex Pharmaceuticals Incorporated	5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en)	2001-08-08	2001-08-30	Luminis Pty Limited	Protein domains and their ligands
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0211019D0 (en)	2002-05-14	2002-06-26	Syngenta Ltd	Novel compounds
EP1518855B1 (en)	2002-06-28	2011-10-26	Astellas Pharma Inc.	Diaminopyrimidinecarboxa mide derivative
MXPA05007503A (es)	2003-01-17	2005-09-21	Warner Lambert Co	Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
WO2005007646A1 (en)	2003-07-10	2005-01-27	Neurogen Corporation	Substituted heterocyclic diarylamine analogues
WO2005013982A1 (en) *	2003-08-06	2005-02-17	Vertex Pharmaceuticals Incorporated	Aminotriazole compounds useful as inhibitors of protein kinases
GB0402653D0 (en)	2004-02-06	2004-03-10	Cyclacel Ltd	Compounds
US7521457B2 (en)	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
FR2896503B1 (fr)	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR20100020454A (ko)	2007-06-08	2010-02-22	바이엘 크롭사이언스 소시에떼아노님	살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en)	2007-10-05	2009-04-09	Targegen Inc.	Anilinopyrimidines as jak kinase inhibitors
GB0719644D0 (en) *	2007-10-05	2007-11-14	Cancer Rec Tech Ltd	Therapeutic compounds and their use
WO2010007756A1 (ja) *	2008-07-14	2010-01-21	塩野義製薬株式会社	Ｔｔｋ阻害作用を有するピリジン誘導体
EP2440204B1 (en)	2009-06-12	2013-12-18	Bristol-Myers Squibb Company	Nicotinamide compounds useful as kinase modulators
DE102009033208A1 (de) *	2009-07-15	2011-01-20	Merck Patent Gmbh	Aminopyridinderivate
EP2493863B1 (en)	2009-10-30	2015-02-25	Janssen Pharmaceutica NV	Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko)	2010-02-01	2012-11-28	닛뽕 케미파 가부시키가이샤	Ｇｐｒ119 작동약
JP2014515029A (ja)	2011-04-29	2014-06-26	アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ	キナーゼ阻害剤

2013
- 2013-01-11 CN CN201380013640.XA patent/CN104169275B/zh not_active Expired - Fee Related
- 2013-01-11 US US14/371,281 patent/US8987311B2/en active Active
- 2013-01-11 ES ES13700829.8T patent/ES2630705T3/es active Active
- 2013-01-11 JP JP2014552312A patent/JP6096807B2/ja not_active Expired - Fee Related
- 2013-01-11 EP EP13700829.8A patent/EP2802577B1/en active Active
- 2013-01-11 WO PCT/US2013/021096 patent/WO2013106614A1/en not_active Ceased

Also Published As

Publication number	Publication date
US20150045347A1 (en)	2015-02-12
CN104169275B (zh)	2017-06-09
JP6096807B2 (ja)	2017-03-15
CN104169275A (zh)	2014-11-26
EP2802577A1 (en)	2014-11-19
EP2802577B1 (en)	2017-03-01
US8987311B2 (en)	2015-03-24
WO2013106614A1 (en)	2013-07-18
JP2015503621A (ja)	2015-02-02

Publication	Publication Date	Title
ES2630705T3 (es)	2017-08-23	Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas
AU2022203948B2 (en)	2023-11-02	Apoptosis-Inducing Agents
ES2652648T3 (es)	2018-02-05	Moduladores P2X7
Wang et al.	2022	The latest FDA-approved pharmaceuticals containing fragments of tailor-made amino acids and fluorine
Bach et al.	2013	Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283
AU2017253937B2 (en)	2021-08-05	Compounds and compositions for treating conditions associated with NLRP activity
JP6162904B2 (ja)	2017-07-12	新規複素環式化合物
ES2439042T3 (es)	2014-01-21	Derivados de 5,6,7,8-tetrahidroimidazo[1,2-a]pirazina como moduladores de P2X7
Meşeli et al.	2021	Design, synthesis, antibacterial activity evaluation and molecular modeling studies of new sulfonamides containing a sulfathiazole moiety
Zender et al.	2013	Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulence
Felicetti et al.	2018	2-Phenylquinoline S. aureus NorA efflux pump inhibitors: evaluation of the importance of methoxy group introduction
Jiang et al.	2021	Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety
IL267215B (en)	2022-09-01	Imidazopyrrolopyridine as inhibitors of the jak family of kinases
Deep et al.	2016	4-Thiazolidinone derivatives: synthesis, antimicrobial, anticancer evaluation and QSAR studies
EP3423451A1 (en)	2019-01-09	Inhibitors of wdr5 protein-protein binding
WO2017140778A1 (en)	2017-08-24	Sulfonylureas and related compounds and use of same
Igoe et al.	2017	Design of a chemical probe for the bromodomain and plant homeodomain finger-containing (BRPF) family of proteins
ES2929140T3 (es)	2022-11-25	Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat
JP7454175B2 (ja)	2024-03-22	抗生物質耐性ブレーカー
CN113302194A (zh)	2021-08-24	作为治疗剂的cGAS活性的抑制剂
Lopez-Tapia et al.	2015	Novel series of dihydropyridinone P2X7 receptor antagonists
ES2796562T3 (es)	2020-11-27	Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
Ye et al.	2020	Discovery of antibacterials that inhibit bacterial RNA polymerase interactions with sigma factors
Khonde et al.	2021	1, 3-Diarylpyrazolyl-acylsulfonamides as potent anti-tuberculosis agents targeting cell wall biosynthesis in Mycobacterium tuberculosis
AR050189A1 (es)	2006-10-04	Derivados sustituidos de propenil piperazina como inhibidores de histona desacetilasa